NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/05/2026
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Tipo de processo
Eventos registrados
Atualização mais recente
Classificação
Tipo de marca
Classes Nice
Data de depósito
Data de registro
Data de expiração
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
Última transação
Escritório responsável
Código da situação
Cadastro oficial
Fundamento do pedido
Primeiro uso
Primeiro uso no comércio
Código do desenho
Tipo de titular
Localização do titular
Examinador
Unidade examinadora
Localização atual
Descrição da marca
The mark consists of the stylized stacked words HONGENE BIOTECH to the left of which is a triangular shape comprised of the letters HG.
Titulares
Representantes
Michael T. Smith Birch Stewart Kolasch & Birch LLP
Classes Nice
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
adjuvants, other than for medical or veterinary purposes; bases in the nature of alkalies being chemical preparations; biochemical catalysts; biological preparations for use in industry and science, other than for medical or veterinary purposes; carbonic hydrates; biochemical catalysts; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical reagents, other than for medical or veterinary purposes; chemical substances for analyses in laboratories, other than for medical or veterinary purposes; chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; diagnostic preparations for research laboratory use; diagnostic preparations, other than for medical or veterinary purposes; enzyme preparations for industrial purposes; enzymes for industrial purposes; ferments for chemical purposes, namely, fermentation extract; glucose for industrial purposes, namely, glucosides; industrial chemicals; isotopes for industrial purposes preparations of microorganisms, other than for medical and veterinary use; salts being chemical preparations; sulfides
Classe 5
biological preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for medical purposes; biological preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for veterinary purposes; capsules sold empty for medicines; chemical preparations for medical purposes for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease; chemical preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for pharmaceutical purposes; chemical preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for veterinary purposes; chemical reagents for medical or veterinary purposes; chemico-pharmaceutical preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease; diagnostic biomarker reagents for medical purposes; diagnostic preparations for medical purposes; diagnostic preparations for medical purposes used by medical laboratories; diagnostic preparations for veterinary purposes; drugs being pharmaceutical preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for medical purposes; enzyme preparations for medical purposes; enzyme preparations for veterinary purposes; enzymes for medical purposes; enzymes for veterinary purposes; ferments for pharmaceutical purposes; immunostimulants; isotopes for medical purposes; medical preparations for slimming purposes; medicinal hair growth preparations; medicines for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss for human purposes; medicines for veterinary purposes for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss; pharmaceutical preparations for treatment and prevention cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss; pharmaceuticals for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss; phosphates for pharmaceutical purposes for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss; preparations of microorganisms for medical or veterinary use; vaccines; veterinary preparations for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss
Histórico de despachos e eventos da marca no USPTO.
25 publicações encontradas
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/05/2026
REGISTERED-PRINCIPAL REGISTER
05/05/2026
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
15/04/2026
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
15/04/2026
STATEMENT OF USE PROCESSING COMPLETE
14/04/2026
USE AMENDMENT FILED
06/11/2025
TEAS STATEMENT OF USE RECEIVED
06/11/2025
TEAS CHANGE OF CORRESPONDENCE RECEIVED
13/05/2025
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
13/05/2025
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
13/05/2025
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
06/05/2025
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/03/2025
PUBLISHED FOR OPPOSITION
11/03/2025
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/03/2025
APPROVED FOR PUB - PRINCIPAL REGISTER
14/02/2025
TEAS/EMAIL CORRESPONDENCE ENTERED
13/02/2025
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/02/2025
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/02/2025
NOTIFICATION OF NON-FINAL ACTION E-MAILED
25/11/2024
NON-FINAL ACTION E-MAILED
25/11/2024
NON-FINAL ACTION WRITTEN
25/11/2024
ASSIGNED TO EXAMINER
25/11/2024
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/11/2024
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/11/2024
NEW APPLICATION ENTERED
10/05/2024
Proteção contínua da sua marca
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.